How does CMV treatment coverage impact newborns and families?

CMV treatment coverage significantly impacts newborns and families by ensuring access to antiviral medications that can reduce the severity of congenital CMV infections. Without insurance coverage, the cost of treatments like valganciclovir can be prohibitive, creating financial stress for families already navigating a newborn's health concerns. Coverage makes these therapies reimbursable, removing cost barriers and enabling timely intervention, which is crucial for preventing lifelong complications such as hearing loss, developmental delays, and vision problems. Advocates argue that this coverage is not only medically beneficial but also cost-effective in the long term, as it reduces the need for extensive special education, healthcare, and support services later in life. The push for treatment coverage aligns with the new guidelines' focus on follow-up care, emphasizing that early and accessible treatment can improve developmental outcomes and quality of life for affected children, while alleviating the emotional and financial burden on their families.

📖 Read the full article: New CMV Pregnancy Guidelines & Treatment Coverage Push